To better determine the therapeutic efficacy of CD20-HSPI&Fe3O4@SiNPs, tumor specimens (after 36 days of AMF treatment) were stained with anti-CD20/PE for immunohistochemical analysis. The gene discussed is MS4A1; the disease is neoplasm.